Ankylosing spondylitis Market: High-Growth Opportunities for Investors to 2034 - DelveInsight

The Ankylosing spondylitis market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Ankylosing spondylitis pipeline products will significantly revolutionize the Ankylosing spondylitis market dynamics.

DelveInsight's "Ankylosing spondylitis Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Ankylosing spondylitis, historical and forecasted epidemiology as well as the Ankylosing spondylitis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Ankylosing spondylitis market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2020 to 2034. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.

To Know in detail about the Ankylosing spondylitis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Ankylosing spondylitis Market Forecast
https://www.delveinsight.com/sample-request/ankylosing-spondylitis-as-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key facts of the Ankylosing spondylitis Market Report:
• The Ankylosing spondylitis market size was valued at USD 4200 Million in the year 2021 and is anticipated to grow with a significant CAGR during the study period (2020-2034).
• In 2023, the United States held the largest share of the Ankylosing Spondylitis market among the 7MM, with an estimated market size of around USD 5 billion.
• Anti-TNF therapies-including CIMZIA, SIMPONI, etanercept, adalimumab, and infliximab account for approximately 60% of the Ankylosing Spondylitis drug market.
• In August 2025, Akeso's monoclonal antibodies, gumokimab and manfidokimab, successfully achieved their primary endpoints in Phase III trials for ankylosing spondylitis (AS) and atopic dermatitis (AD). In the NCT06378697 study evaluating gumokimab (AK111) for AS, the treatment rapidly reduced inflammation-related symptoms, improved physical function, and enhanced patient quality of life. Additionally, gumokimab increased ASAS20 scores, showing a 20% improvement in AS symptoms from baseline over the 61-week study period.
• In February 2025, UCB Canada Inc. has successfully concluded negotiations with the pan-Canadian Pharmaceutical Alliance (pCPA) for BIMZELX® (bimekizumab), following positive reimbursement recommendations from both Canada's Drug Agency (CDA) and Quebec's Institut National d'Excellence en Santé et en Services Sociaux (INESSS). These endorsements pertain to the treatment of adults with active psoriatic arthritis (PsA) and ankylosing spondylitis (AS). BIMZELX® is the first and only biologic approved in Canada that inhibits both IL-17A and IL-17F. Health Canada authorized its use for active PsA on February 23, 2024, and for axial spondyloarthritis, including AS, on March 11, 2024. The recent successful negotiations with pCPA are anticipated to facilitate public reimbursement, enhancing patient access to this innovative therapy.
• In January 2025, Screening is currently underway for adults with active axial spondyloarthritis (axSpA), including ankylosing spondylitis, for a Phase 2 clinical trial in Germany testing sonelokimab. This nanobody, developed by Moonlake Immunotherapeutics, is being evaluated for its potential in treating inflammatory diseases of the skin and joints. The open-label study, named S-OLARIS (EudraCT 2024-513498-36), aims to assess the efficacy of sonelokimab in reducing inflammation in the spine and sacroiliac joints, which connect the spine to the pelvis. The trial plans to enroll approximately 25 patients, all of whom will receive a 60 mg dose of sonelokimab via subcutaneous injection.
• In December 2024, Neuron23® Inc., a clinical-stage biotechnology company dedicated to precision medicines for genetically defined neurological and immunological diseases, announced the commencement of dosing in a Phase 1 clinical trial of NEU-111 in healthy volunteers. NEU-111 is a highly selective oral allosteric inhibitor of tyrosine kinase 2 (TYK2), a member of the JAK protein family involved in pathological immune signaling. With best-in-class potential, NEU-111 reduces signaling through multiple cytokine receptors, including those for interleukin (IL)-12, IL-23, and interferon (IFN). TYK2 is associated with various immune-mediated inflammatory diseases, including ankylosing spondylitis.
• In 2023, the total prevalent population of ankylosing spondylitis in the 7MM region was approximately 2,300,000, with the highest number of cases observed in the United States.
• In the 7MM, approximately 1,130,000 cases of diagnosed ankylosing spondylitis were reported in 2023. According to the analysis, these cases are projected to increase by 2034 with a moderate compound annual growth rate (CAGR).
• In 2023, the United States reported the highest number of age-specific prevalent cases, with approximately 270,000 cases among individuals aged 40-59 years, followed by those under 40 years of age.
• In 2023, Italy had the highest number of diagnosed prevalent cases of ankylosing spondylitis in the EU4 region, totaling approximately 192,000 cases.
• Key Ankylosing spondylitis Companies: Kinevant Sciences, MoonLake Immunotherapeutics, Qyuns Therapeutics, Suzhou Zelgen Biopharmaceuticals, Jiangsu HengRui MedicIne, Suzhou Zelgen Biopharmaceuticals, Amgen, and others
• Key Ankylosing spondylitis Therapies: KIN-1901, Sonelokimab, QX 002N, SHR-1314, SHR0302, Jaktinib, Apremilast, and others
• The Ankylosing spondylitis epidemiology based on gender analyzed that Ankylosing spondylitis is more common in males than females

Ankylosing spondylitis Overview
Ankylosing spondylitis (AS) is a chronic inflammatory disease that primarily affects the spine and sacroiliac joints, leading to pain and stiffness. Over time, AS can cause the vertebrae in the spine to fuse, resulting in a loss of flexibility and a hunched-forward posture. In severe cases, it can lead to the spine becoming inflexible and rigid.

Get a Free sample for the Ankylosing spondylitis Market Report -
https://www.delveinsight.com/report-store/ankylosing-spondylitis-as-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Ankylosing spondylitis Market
The dynamics of the Ankylosing spondylitis market are anticipated to change in the coming years owing to the expected launch of emerging therapies and others during the forecasted period 2020-2034.

Ankylosing spondylitis Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Ankylosing spondylitis Epidemiology Segmentation:
The Ankylosing spondylitis market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
• Total Prevalent cases of Ankylosing Spondylitis in the 7MM
• Diagnosed Prevalent cases of Ankylosing Spondylitis in the 7MM
• Age-specific Diagnosed Prevalent Cases of Ankylosing Spondylitis in 7MM
• Treated cases of Ankylosing Spondylitis in the 7MM
• Gene-specific Diagnosed Prevalent cases of Ankylosing Spondylitis in the 7MM
• Gender-specific Diagnosed Prevalent cases of Ankylosing Spondylitis in the 7MM

Download the report to understand which factors are driving Ankylosing spondylitis epidemiology trends @ Ankylosing spondylitis Epidemiological Insights
https://www.delveinsight.com/sample-request/ankylosing-spondylitis-as-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Ankylosing spondylitis Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Ankylosing spondylitis market or expected to get launched during the study period. The analysis covers Ankylosing spondylitis market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Ankylosing spondylitis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

To know more about Ankylosing spondylitis treatment, visit @ Ankylosing spondylitis Medications
https://www.delveinsight.com/sample-request/ankylosing-spondylitis-as-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Ankylosing spondylitis Therapies and Key Companies
• KIN-1901: Kinevant Sciences
• Sonelokimab: MoonLake Immunotherapeutics
• QX 002N: Qyuns Therapeutics
• SHR-1314: Suzhou Zelgen Biopharmaceuticals
• SHR0302: Jiangsu HengRui MedicIne
• Jaktinib: Suzhou Zelgen Biopharmaceuticals
• Apremilast: Amgen

Ankylosing spondylitis Market Strengths
• Certain initiatives have been taken by private and government organizations to raise awareness about the disease. The Spondylitis Association of America (SAA) began officially celebrating SpA Awareness Month in May.
• There has been an increase in pharmaceutical companies' investment in the research and development of drugs.

Ankylosing spondylitis Market Opportunities
• Several pharmaceutical key players have taken the initiative to meet the unmet needs of the Ankylosing Spondylitis market's present situation.
• The prevalence of Ankylosing Spondylitis diagnosis codes more than doubled between 2006 and 2016; increase in prevalence creates a lucrative opportunity for the Ankylosing Spondylitis market.

Scope of the Ankylosing spondylitis Market Report
• Study Period: 2020-2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Ankylosing spondylitis Companies: Kinevant Sciences, MoonLake Immunotherapeutics, Qyuns Therapeutics, Suzhou Zelgen Biopharmaceuticals, Jiangsu HengRui MedicIne, Suzhou Zelgen Biopharmaceuticals, Amgen, and others
• Key Ankylosing spondylitis Therapies: KIN-1901, Sonelokimab, QX 002N, SHR-1314, SHR0302, Jaktinib, Apremilast, and others
• Ankylosing spondylitis Therapeutic Assessment: Ankylosing spondylitis current marketed and Ankylosing spondylitis emerging therapies
• Ankylosing spondylitis Market Dynamics: Ankylosing spondylitis market drivers and Ankylosing spondylitis market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Ankylosing spondylitis Unmet Needs, KOL's views, Analyst's views, Ankylosing spondylitis Market Access and Reimbursement

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

This release was published on openPR.